Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Jan;64(1):6–12. doi: 10.1136/jnnp.64.1.6

A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia

T Odergren 1, H Hjaltason 1, S Kaakkola 1, G Solders 1, J Hanko 1, C Fehling 1, R Marttila 1, H Lundh 1, S Gedin 1, I Westergren 1, A Richardson 1, C Dott 1, H Cohen 1
PMCID: PMC2169916  PMID: 9436720

Abstract

OBJECTIVE—This study was designed to establish whether a ratio of three units of Dysport® is equivalent to one unit of Botox® for the treatment of cervical dystonia.
METHODS—Patients with predominantly rotational cervical dystonia, and a minimum of four previous Botox treatments, were randomised to receive either the clinically indicated dose of Botox or three times that dose in Dysport units. Study botulinum toxin was administered in a double blind fashion, to one or more clinically indicated muscles, at one or more sites per muscle. Patients returned for assessment two, four, eight, and 12 weeks after treatment.
RESULTS—A total of 73 patients (Dysport, 38; Botox, 35) were entered. The Dysport group received a mean (SD) dose of 477 (131) (range 240-720) Dysport units, and the Botox group received a mean (SD) dose of 152 (45) (range 70-240) Botox units. The mean (SEM) post-treatment Tsui scores for the Dysport group (4.8 (0.3)) and the Botox group (5.0 (0.3)) were not statistically different (p=0.66). The study had 91% power to detect a clinically significant difference of two points. Both groups showed substantial improvement in Tsui score by week 2 (mean (SD); Dysport, 46 (28)%; Botox, 37 (28)%), with a peak effect at week 4 (mean (SD); Dysport, 49 (29)%; Botox, 44 (28)%). A similar response profile was seen for other assessments of efficacy. The duration of effect, assessed by time to retreatment, was also similar (mean (SD); Dysport, 83.9 (13.6) days; Botox, 80.7 (14.4) days; p=0.85). During the study 22 of 38 (58%) Dysport patients reported 39 adverse events, and 24 of 35 (69%) Botox patients reported 56 adverse events (p=0.35). A global assessment of efficacy and safety considered that 29 of 38 (76%) Dysport patients and 23 of 35 (66%) Botox patients were treatment successes (p=0.32).
CONCLUSION—Patients with predominantly rotational cervical dystonia treated with the clinically indicated dose of Botox or three times that dose in Dysport units show similar improvements and do not have significantly different safety profiles.



Full Text

The Full Text of this article is available as a PDF (125.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Claus D., Druschky A., Erbguth F. Botulinum toxin: influence on respiratory heart rate variation. Mov Disord. 1995 Sep;10(5):574–579. doi: 10.1002/mds.870100508. [DOI] [PubMed] [Google Scholar]
  2. Girlanda P., Vita G., Nicolosi C., Milone S., Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry. 1992 Sep;55(9):844–845. doi: 10.1136/jnnp.55.9.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hambleton P., Pickett A. M. Potency equivalence of botulinum toxin preparations. J R Soc Med. 1994 Nov;87(11):719–719. [PMC free article] [PubMed] [Google Scholar]
  4. Marion M. H., Sheehy M., Sangla S., Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):102–103. doi: 10.1136/jnnp.59.1.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Nutt J. G., Muenter M. D., Aronson A., Kurland L. T., Melton L. J., 3rd Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord. 1988;3(3):188–194. doi: 10.1002/mds.870030302. [DOI] [PubMed] [Google Scholar]
  6. Odergren T., Tollbäck A., Borg J. Efficacy of botulinum toxin for cervical dystonia. A comparison of methods for evaluation. Scand J Rehabil Med. 1994 Dec;26(4):191–195. [PubMed] [Google Scholar]
  7. Odergren T., Tollbäck A., Borg J. Electromyographic single motor unit potentials after repeated botulinum toxin treatments in cervical dystonia. Electroencephalogr Clin Neurophysiol. 1994 Oct;93(5):325–329. doi: 10.1016/0168-5597(94)90119-8. [DOI] [PubMed] [Google Scholar]
  8. Olney R. K., Aminoff M. J., Gelb D. J., Lowenstein D. H. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology. 1988 Nov;38(11):1780–1783. doi: 10.1212/wnl.38.11.1780. [DOI] [PubMed] [Google Scholar]
  9. Poewe W., Deuschl G., Nebe A., Feifel E., Wissel J., Benecke R., Kessler K. R., Ceballos-Baumann A. O., Ohly A., Oertel W. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 1998 Jan;64(1):13–17. doi: 10.1136/jnnp.64.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord. 1997 Jan;12(1):100–102. doi: 10.1002/mds.870120117. [DOI] [PubMed] [Google Scholar]
  11. Tsui J. K., Eisen A., Stoessl A. J., Calne S., Calne D. B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986 Aug 2;2(8501):245–247. doi: 10.1016/s0140-6736(86)92070-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES